These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 31703079)
1. Serum miR-33a is associated with steatosis and inflammation in patients with non-alcoholic fatty liver disease after liver transplantation. Erhartova D; Cahova M; Dankova H; Heczkova M; Mikova I; Sticova E; Spicak J; Seda O; Trunecka P PLoS One; 2019; 14(11):e0224820. PubMed ID: 31703079 [TBL] [Abstract][Full Text] [Related]
2. Elevated miR-33a and miR-224 in steatotic chronic hepatitis C liver biopsies. Lendvai G; Jármay K; Karácsony G; Halász T; Kovalszky I; Baghy K; Wittmann T; Schaff Z; Kiss A World J Gastroenterol; 2014 Nov; 20(41):15343-50. PubMed ID: 25386083 [TBL] [Abstract][Full Text] [Related]
3. Association of Circulating Serum miR-34a and miR-122 with Dyslipidemia among Patients with Non-Alcoholic Fatty Liver Disease. Salvoza NC; Klinzing DC; Gopez-Cervantes J; Baclig MO PLoS One; 2016; 11(4):e0153497. PubMed ID: 27077736 [TBL] [Abstract][Full Text] [Related]
4. Hepatic miR-33a/miR-144 and their target gene ABCA1 are associated with steatohepatitis in morbidly obese subjects. Vega-Badillo J; Gutiérrez-Vidal R; Hernández-Pérez HA; Villamil-Ramírez H; León-Mimila P; Sánchez-Muñoz F; Morán-Ramos S; Larrieta-Carrasco E; Fernández-Silva I; Méndez-Sánchez N; Tovar AR; Campos-Pérez F; Villarreal-Molina T; Hernández-Pando R; Aguilar-Salinas CA; Canizales-Quinteros S Liver Int; 2016 Sep; 36(9):1383-91. PubMed ID: 26945479 [TBL] [Abstract][Full Text] [Related]
5. Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. Miyaaki H; Ichikawa T; Kamo Y; Taura N; Honda T; Shibata H; Milazzo M; Fornari F; Gramantieri L; Bolondi L; Nakao K Liver Int; 2014 Aug; 34(7):e302-7. PubMed ID: 24313922 [TBL] [Abstract][Full Text] [Related]
6. Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan. Akuta N; Kawamura Y; Suzuki F; Saitoh S; Arase Y; Kunimoto H; Sorin Y; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Suzuki Y; Kobayashi M; Ikeda K; Kumada H Hepatol Int; 2016 Jul; 10(4):647-56. PubMed ID: 27074850 [TBL] [Abstract][Full Text] [Related]
7. Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma. Akuta N; Kawamura Y; Suzuki F; Saitoh S; Arase Y; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Suzuki Y; Kobayashi M; Ikeda K; Kumada H BMC Gastroenterol; 2016 Dec; 16(1):141. PubMed ID: 27955628 [TBL] [Abstract][Full Text] [Related]
8. Quantitative Prediction of Steatosis in Patients with Non-Alcoholic Fatty Liver by Means of Hepatic MicroRNAs Present in Serum and Correlating with Hepatic Fat. Quintás G; Caiment F; Rienda I; Pérez-Rojas J; Pareja E; Castell JV; Jover R Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012565 [TBL] [Abstract][Full Text] [Related]
10. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Pirola CJ; Fernández Gianotti T; Castaño GO; Mallardi P; San Martino J; Mora Gonzalez Lopez Ledesma M; Flichman D; Mirshahi F; Sanyal AJ; Sookoian S Gut; 2015 May; 64(5):800-12. PubMed ID: 24973316 [TBL] [Abstract][Full Text] [Related]
11. Histologically proven non-alcoholic fatty liver disease and clinically related factors in recipients after liver transplantation. Kim H; Lee K; Lee KW; Yi NJ; Lee HW; Hong G; Choi Y; You T; Suh SW; Jang JJ; Suh KS Clin Transplant; 2014 May; 28(5):521-9. PubMed ID: 24579874 [TBL] [Abstract][Full Text] [Related]
12. Performance of Serum microRNAs -122, -192 and -21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis. Becker PP; Rau M; Schmitt J; Malsch C; Hammer C; Bantel H; Müllhaupt B; Geier A PLoS One; 2015; 10(11):e0142661. PubMed ID: 26565986 [TBL] [Abstract][Full Text] [Related]
16. Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes. Bayliss J; Ooi GJ; De Nardo W; Shah YJH; Montgomery MK; McLean C; Kemp W; Roberts SK; Brown WA; Burton PR; Watt MJ Front Endocrinol (Lausanne); 2021; 12():642432. PubMed ID: 33746906 [TBL] [Abstract][Full Text] [Related]
17. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients. Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071 [TBL] [Abstract][Full Text] [Related]
18. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients. Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434 [TBL] [Abstract][Full Text] [Related]